Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.
Nepuvibart (ZRC3308-B10) is a monoclonal antibody of the IgG1 subtype, designed specifically to target SARS-CoV-2. It exhibits high binding affinity to a distinct, non-competing epitope located on the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. For enhanced therapeutic efficacy, Nepuvibart can be administered in conjunction with ZRC3308-A7 in a 1:1 ratio. This combination has been shown to be effective in the prevention of COVID-19, as well as in the treatment of the early stages of the disease prior to the onset of severe symptoms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
